NR2F6

Antagonists

The Master Regulator of T Cell Activation in immune-oncology.

Disease
Cancer
Status
Preclinical
The Target

NR2F6 is an orphan nuclear receptor that controls the activation of T lymphocytes regulating the expression of key factors including interleukin 2 (IL-2) and interferon γ (IFN γ).

NR2F6 is an essential signalling node governing host-tumour interactions at the crossroads between inflammation and cancer. Studies have shown that NR2F6-knockout mice demonstrate a reduced tumour growth due to an increased anti-cancer immune response, making NR2F6 a target for next generation immuno-oncology therapies.

Our Research

We have developed the first potent and selective small molecule NR2F6 antagonist able to inhibit its nuclear receptor functions in T cells. Treatment with our lead compound significantly mitigates tumour growth in multiple pre-clinical syngeneic cancer mouse models